VTVT vTv Therapeutics

vTv Therapeutics to Present Posters at Two Scientific Conferences in September

vTv Therapeutics to Present Posters at Two Scientific Conferences in September

 Presenting New Clinical Data from Phase 2 Study in Type 1 Diabetes with Liver Selective GKA Program

Pre-Clinical Data in NASH with the NRF2/Bach1 Program 

HIGH POINT, N.C., Sept. 11, 2019 (GLOBE NEWSWIRE) -- (Nasdaq: VTVT), a clinical-stage biopharmaceutical company with leading programs focused on the development of orally administered treatments for diabetes, Alzheimer’s disease and inflammatory disorders, today announced it will be presenting posters with new clinical and pre-clinical data from the company’s Liver Selective GKA Program and its NRF2/Bach1 program at two upcoming European scientific conferences.

Details of the posters are listed below:

55th Annual Meeting of the European Association for the Study of Diabetes

The conference is being held in Barcelona, Spain from September 16-20, 2019

  • Poster Title: Results from the sentinel and learning Phase of the Simplici-T1 study, the First Clinical Trial to Test Activation of Glucokinase as an Adjunctive Treatment for Type 1 Diabetes
  • Poster Number: 729 
  • Date and Time: Wednesday, September 18, 13:15-14:15 CEST

EASL Non-Alcoholic Fatty Liver Disease (NAFLD) Summit 2019

The conference is hosted by The European Association for the Study of the Liver (EASL) being held in Seville, Spain from September 26-28, 2019

  • Poster Title: Non-electrophilic activation of the NRF2 pathway ameliorated experimental Nonalcoholic Steatohepatitis
  • Abstract Number: 173
  • Date and Time: Sept 28, 2019, 10:25-10:45 CEST

About vTv Therapeutics

vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing oral small molecule drug candidates. vTv has a pipeline of clinical drug candidates led by programs for the treatment of diabetes, Alzheimer’s disease, and inflammatory disorders. vTv’s development partners are pursuing additional indications in type 2 diabetes, Chronic Obstructive Pulmonary Disease (COPD), and genetic mitochondrial diseases.

Contacts

Investors:

vTv Therapeutics Inc.

or



Media:

Josh Vlasto

212-572-5969

EN
11/09/2019

Underlying

VTVTvTv Therapeutics

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on vTv Therapeutics

 PRESS RELEASE
Free
VTVT vTv Therapeutic...

vTv Therapeutics to Participate in Upcoming Investor Conferences

vTv Therapeutics to Participate in Upcoming Investor Conferences HIGH POINT, N.C., Feb. 13, 2026 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a novel, potential first-in-class oral adjunctive therapy to insulin being investigated for the treatment of type 1 diabetes (T1D), today announced that management will participate in the following upcoming investor conferences: Oppenheimer 36th Annual Healthcare Life Sciences ConferenceDate: Thursday, February 26, 2026Time: 11:20 AM ETFormat: Presentat...

February 13, 2026 1 EN
 PRESS RELEASE
Free
VTVT vTv Therapeutic...

vTv Therapeutics Amends License Agreement with Newsoara Biopharma Co. ...

vTv Therapeutics Amends License Agreement with Newsoara Biopharma Co. Ltd. for PDE4 inhibitor, HPP737 Strategic amendment transforms regional partnership into global collaboration; Newsoara gains exclusive worldwide license to develop and commercialize novel PDE4 inhibitor vTv to receive $20 million upfront payment immediately upon execution of the amended license agreement HIGH POINT, N.C., Feb. 02, 2026 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a novel, potential first-in-class oral adj...

February 2, 2026 1 EN
 PRESS RELEASE
Free
VTVT vTv Therapeutic...

vTv Therapeutics and M42’s IROS Announce Submission of Phase 2 Clinica...

vTv Therapeutics and M42’s IROS Announce Submission of Phase 2 Clinical Study Protocol for Cadisegliatin in Type 2 Diabetes to the United Arab Emirates Department of Health Trial to assess cadisegliatin as potential adjunctive therapy to insulin in patients with T2D HIGH POINT, N.C., Dec. 18, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company, today announced a Phase 2 clinical study protocol developed in collaboration with M42’s Insights Research Organization & Solutions (IROS), a leading United Arab Emirates (UAE)-based contract resea...

December 18, 2025 1 EN
 PRESS RELEASE
Free
VTVT vTv Therapeutic...

vTv Therapeutics Reports Third Quarter 2025 Financial Results and Prov...

vTv Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update Topline Phase 3 CATT1 data for cadisegliatin in type 1 diabetes expected second half 2026  $80 million private placement strengthens balance sheet and supports Phase 3 CATT1 completion Announced issuance of new U.S. patent covering crystalline salts and co-crystals forms of cadisegliatin with exclusivity expected out to 2041 HIGH POINT, N.C., Nov. 06, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliati...

November 6, 2025 1 EN
 PRESS RELEASE
Free
VTVT vTv Therapeutic...

vTv Therapeutics Announces New Appointments to its Scientific Advisory...

vTv Therapeutics Announces New Appointments to its Scientific Advisory Board Board to offer guidance on clinical development of cadisegliatin for type 1 diabetes as company has initiated Phase 3 trials HIGH POINT, N.C., Oct. 09, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, today announced the appointment of Alfonso Galderisi, MD, PhD, Mark Evans, MD, Chantal Mathieu, MD, PhD, and Klara Klein, MD, PhD, to its Scientific Advisory Board (SAB). The SAB, composed of internationally recognize...

October 9, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch